Clinical application of mesenchymal stem cells in rheumatic diseases

被引:0
作者
Yajing Wang
Dan Ma
Zewen Wu
Baoqi Yang
Rong Li
Xingxing Zhao
Helin Yang
Liyun Zhang
机构
[1] Tongji Shanxi Hospital,Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences
[2] Shanxi University of Chinese Medicine,undefined
来源
Stem Cell Research & Therapy | / 12卷
关键词
Mesenchymal stem cells; Rheumatic diseases; Clinical application;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from mesoderm during early development that are characterized by high self-renewal ability and multidirectional differentiation potential. These cells are present various tissues in the human body and can be cultured in vitro. Under specific conditions, MSCs can differentiate into osteoblasts, neuron-like cells, adipocytes and muscle cells and so on, therefore, have a great application value in cell replacement therapy and tissue repair. In recent years, the application of MSCs in rheumatic diseases has received increasing attention. On the one hand, MSCs have the ability to differentiate into bone and cartilage cells; on the other hand, these stem cells are also involved in immune regulation, resulting in the alleviation of inflammation and anti-fibrotic properties and the promotion of vascular repair, thus bringing new hope for the treatment of rheumatic diseases. This article reviews the clinical progress in MSC application for the treatment of rheumatic diseases.
引用
收藏
相关论文
共 313 条
[21]  
Keene CD(2018)Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase IA Clinical Trial Stem Cells Transl Med 7 636-867
[22]  
Ortiz-Gonzalez XR(2020)A significant decrease of BAFF, APRIL, and BAFF receptors following mesenchymal stem cell transplantation in patients with refractory rheumatoid arthritis Gene 732 144336-3618
[23]  
Paul D(2009)Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine Ann Rheum Dis 68 863-471
[24]  
Samuel SM(2012)Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis Rheumatol Int 32 3613-73
[25]  
Maulik N(2006)Ankylosing spondylitis and bowel disease Best Pract Res Clin Rheumatol 20 451-351
[26]  
Ju S(2015)Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis Ann Rheum Dis 74 65-1082
[27]  
Teng GJ(2015)Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: the DESIR cohort Jt Bone Spine 82 345-R444
[28]  
Lu H(2009)Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed J Clin Investig 119 1079-1559
[29]  
Jin J(2005)Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Arthritis Res Therapy 7 R439-321
[30]  
Zhang Y(2014)Spondyloarthritis: from unifying concepts to improved treatment Rheumatology (Oxford) 53 1547-1303